| 2016-10-19 06:25:27|
PRTO 06:25 10/19 10/19/16
Proteon Therapeutics initiated with an Outperform at Cowen
Cowen analyst Boris Peaker initiated Proteon Therapeutics with an Outperform saying risk/reward ahead of vonapanitase's first Phase 3 readout in December is favorable. Peaker said Phase 2 data was was better than investors currently assume with impressive rAVF results that were highly clinically meaningful.